FILE-004 · OPEN
◉ Cold Open — A Kitchen at 6:15 A.M., Somewhere in the United States
On the counter, next to the coffee, a plastic weekly pillbox. Monday through Sunday, seven small compartments. Inside most of them, in most American kitchens where a member of the household is over sixty, is a statin.
The combination did not always look this way. In March 2026, a multi-society update to the American cholesterol-management guideline was released. In July, a JAMA analysis reported what the new document did to the American prescription pad.
Statin eligibility expanded by twenty-one and a half million adults. In the seventy-to-seventy-nine age band, more than ninety-three percent of adults now qualify.
The American Heart Association and the American College of Cardiology do not, as a rule, publish their guidelines on a schedule the public tracks. Cardiology guidelines arrive when the sponsoring societies believe the evidence has changed. In March 2026, a multi-society update to the American cholesterol-management guideline was released — the first substantive revision to primary-prevention criteria in eight years.
In July, an analysis in the Journal of the American Medical Association, authored by researchers at the University of Pittsburgh and the VA Pittsburgh Healthcare System, reported the new document’s reach. Statin eligibility expanded by 21.5 million adults. Total eligibility now stands at roughly 87.5 million, or 56.6 percent of adults aged 30 to 79.
Observation .
The age band this newsletter’s reader most often occupies is where the change is largest. In the seventy-to-seventy-nine group, ninety-three percent of adults now qualify for consideration under the new criteria. In the sixty-to-sixty-nine group, eighty-five percent do. The age range for risk assessment itself was widened, from the 40-to-75 window used since 2013 to 30-to-79 now.
Two changes drove most of the expansion. First, the guideline adopted a new risk-estimation tool called the PREVENT equations, replacing the pooled cohort equations that had governed the previous decade of prescribing. Second, the low-risk threshold was lowered: patients previously classified as low risk now fall into borderline or intermediate categories, where a statin is at least discussed.
The change was defended in the accompanying editorials as evidence-driven, as most such changes are. Statins are well-studied. In secondary prevention — for patients who have already had a cardiovascular event — the evidence for benefit is strong across decades of large randomized trials. In primary prevention — for patients who have not — the evidence is present but more modest, with absolute risk reduction that varies substantially by baseline risk. The 2026 guideline places more Americans in the primary-prevention room.
Pattern .
The Archivist would note that the direction of American cholesterol guidelines has been consistent for nearly forty years. The National Cholesterol Education Program, launched in 1985 by the National Heart, Lung, and Blood Institute, published its first Adult Treatment Panel report in 1988. ATP II followed in 1993, ATP III in 2001. Each report broadened the definition of who should be treated.
Then, in November 2013, the ACC and AHA published a new guideline that superseded the NCEP series and shifted the operating principle from LDL-target-based treatment to risk-based treatment. That shift, per a widely-cited 2014 analysis in the New England Journal of Medicine, made roughly 12.8 million additional Americans eligible for statin therapy at a single stroke.
The 2013 change was controversial. Editorials in the same journal noted that the new risk calculator appeared to overestimate risk in some populations by as much as seventy-five to a hundred percent when compared against contemporary cohorts. The debate did not reverse the guideline. It refined the calculator, and the guideline moved on.
The pattern is worth stating plainly. In 1988, statins were nine months into their commercial life; the first Adult Treatment Panel report was cautious about who should take them. In 2013, the ACC and AHA moved to risk-based treatment and added twelve million adults to the eligible list. In 2026, the same societies moved the risk calculator again, and added another twenty-one and a half million. In each cycle, the reasoning was current. In each cycle, the direction was outward.
Working Theory.
What the reader is watching, across four decades of cholesterol guidelines, is not necessarily error and not necessarily overreach. Statins do reduce cardiovascular events. That much is not in dispute at the level of the large randomized trials. What the reader is watching is a specific institutional pattern: each cycle of guideline updates has moved the treated population outward, and each cycle has done so in the name of evidence that arrives in the same direction it moved the last time.
The Field Editor prefers to phrase this differently. A guideline that moves in one direction with every revision, over forty years, is not one guideline. It is a policy trajectory. Whether the trajectory is correct is a matter for cardiologists. Whether it has produced better outcomes at the population level, particularly in primary prevention for adults over seventy, is a question genuinely disputed in the current literature.
The reader’s practical position is this: a physician who recommends a statin under the new guideline is now supported by an updated risk calculator using more recent data, and by a society consensus that has held for forty years. The evidence for or against, in a given case, still requires the same conversation with the same physician it always has. The number that changed in March is the size of the room in which that conversation is now being held.
Agent’s Recommendation
The archive suggests four small acts of observation this week — each is a question a reader can ask or a document a reader can read.
-
At your next appointment, ask which risk calculator your physician is using. If it is the pooled cohort equations, ask whether the new PREVENT equations change the estimate. Both are free to run on any device.
-
Read the American Heart Association’s plain-language summary of the 2026 cholesterol guideline at heart.org . The full multi-society document is technical; the summary is short and specific.
-
Ask your physician for the numbers the guideline is calculated from — LDL cholesterol, non-HDL cholesterol, and estimated ten-year ASCVD risk. Writing them down makes future comparisons meaningful.
-
Look up the 2018 cholesterol guideline for reference. The comparison between the 2018 and 2026 documents is more informative than either one read alone.
◌ Unresolved Transmission
Whether the next US Preventive Services Task Force review of statin primary prevention arrives with a different judgment than the cardiology societies — or the same one.
— Filed by The Archivist
Bureau of Body Signals · FILE-004 · OPEN